Previous 10 | Next 10 |
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors PR Newswire SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pat...
Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy PR Newswire SAN DIEGO , April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatmen...
2023-03-17 17:22:43 ET Gainers: SolarEdge Technologies ( SEDG ) +6% . SuRo Capital ( SSSS ) +5% . Cincinnati Financial Corporation ( CINF ) +5% . Northern Trust Corporation ( NTRS ) +4% . Arch Capital Group ( ACGL ) +4% . ...
2023-03-09 17:56:27 ET Poseida Therapeutics press release ( NASDAQ: PSTX ): Q4 GAAP EPS of -$0.39 misses by $0.56 . Revenue of $10.05M (-67.8% Y/Y) misses by $21.7M . For further details see: Poseida Therapeutics GAAP EPS of -$0.39 misses by $0.56, revenu...
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 PR Newswire Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society for Medical Oncology Immu...
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board PR Newswire SAN DIEGO , March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class...
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations PR Newswire Vir...
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference PR Newswire SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments ...
Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 PR Newswire SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX...
Summary Poseida is emerging as a leader in the allogeneic cell therapy field. A deal struck with Swiss Pharma giant Roche last year involved a $110m upfront payment plus as much as $6bn in development and commercial milestone payments. The 2 companies will develop allogeneic cell th...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Inc. Website:
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...